Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes. Circulating ADAMTS13-specific immune complexes have been described in acquired thrombotic thrombocytopenic purpura patients, however, the prevalence and persistence of these immune complexes over time has hitherto remained elusive. Here, we analyzed a large cohort of patients with acquired thrombotic thrombocytopenic purpura for the presence of free and complexed anti-ADAMTS13 antibodies. In the acute phase (n=68), 100% of patients had free IgG antibodies and 97% had ADAMTS13-specific immune complexes. In remission (n=28), 75% of patients had free antibodies (mainly IgG) and 93% had ADAMTS13-specific immune complexes. Free antibodies were mainly of subclasses IgG1 and IgG4, whereas IgG4 was by far the most prevalent in ADAMTS13-specific immune complexes. Comparison of ADAMTS13 inhibitor and anti-ADAMTS13 IgG (total and subclasses) antibody titers in acute phase and in remission samples showed a statistically significant decrease in all parameters in remission.
ABSTRACT
Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes. Circulating ADAMTS13-specific immune complexes have been described in acquired thrombotic thrombocytopenic purpura patients, however, the prevalence and persistence of these immune complexes over time has hitherto remained elusive. Here, we analyzed a large cohort of patients with acquired thrombotic thrombocytopenic purpura for the presence of free and complexed anti-ADAMTS13 antibodies. In the acute phase (n=68), 100% of patients had free IgG antibodies and 97% had ADAMTS13-specific immune complexes. In remission (n=28), 75% of patients had free antibodies (mainly IgG) and 93% had ADAMTS13-specific immune complexes. Free antibodies were mainly of subclasses IgG1 and IgG4, whereas IgG4 was by far the most prevalent in ADAMTS13-specific immune complexes. Comparison of ADAMTS13 inhibitor and anti-ADAMTS13 IgG (total and subclasses) antibody titers in acute phase and in remission samples showed a statistically significant decrease in all parameters in remission.
Although non-significant, a trend towards reduced or undetectable titers in remission was also observed for ADAMTS13-specific immune complexes of subclasses IgG1, IgG2 and IgG3. For IgG4, no such trend was discernible; IgG4 immune complexes persisted over years, even in patients who had been treated with rituximab and who showed no features suggesting relapse.
INTRODUCTION
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by hemolytic anemia, severe thrombocytopenia and fluctuating organ dysfunction (mainly renal and cerebral) due to the deposition of platelet-rich thrombi in the microvasculature. 1 A severe deficiency of the plasma enzyme ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 repeats), due to genetic mutations (congenital) 2 or anti-ADAMTS13
autoantibodies (acquired), 3;4 is the main cause in the pathogenesis of TTP. Autoantibodies against ADAMTS13 are predominantly of the IgG class, [5] [6] [7] particularly subclasses IgG4 and IgG1, [8] [9] [10] but also autoantibodies belonging to classes IgM and IgA have been described. 5;9-11 Elevated levels of soluble circulating autoantibody-antigen immune complexes (ICs) are the hallmark of many autoimmune diseases. [12] [13] [14] Deposition of circulating ICs in tissues, mainly in capillary beds, promoting inflammation and tissue damage, is the most relevant pathological mechanism underlying IC-mediated diseases. Early reports attributed the benefit of plasma exchange (PEX) therapy in patients with TTP in part to the removal of circulating ICs, 15;16 however, their presence remained hypothetical for years as the underlying mechanism leading to TTP was not yet identified. 17;18 With the isolation of inhibiting IgG antibodies against ADAMTS13 from plasma of TTP patients, the presence of ADAMTS13-specific ICs became plausible 19 , with the following observations supporting their existence: (i) removal of anti-ADAMTS13 IgG antibodies also removed measurable residual ADAMTS13 antigen, 20 (ii) residual ADAMTS13 activity was no longer measurable after plasma IgG depletion, 21 and (iii)
human IgGs bound to ADAMTS13 were identified by adaptation of a commercial ADAMTS13
antigen ELISA. 22 Recently, we demonstrated the presence of ADAMTS13-specific ICs in a patient with refractory acquired TTP (aTTP) using a co-immunoprecipitation technique (co-IP). 23 This observation prompted us to investigate the prevalence of ADAMTS13-specific ICs in a large cohort of patients with aTTP during the acute phase and in remission. Results are discussed in terms of ADAMTS13-specific ICs as a novel biomarker that may contribute to a better understanding of aTTP pathogenesis and responsiveness to treatment.
METHODS

Patient plasma samples
The study included 78 patients diagnosed with idiopathic aTTP. 
ADAMTS13 assays
ADAMTS13 activity (ADAMTS13:Ac) and ADAMTS13 functional inhibitor titers were measured using fluorometric FRETS-VWF73 assay as described. 24;25 The limit of quantification of the ADAMTS13:Ac was 0.05 U/mL (5%); values <0.10 U/mL (<10%) were considered severely reduced; levels of 0.10 -0.50 U/mL as reduced and levels >0.5 U/mL as normal. An inhibitor titer <0.7 BU/mL was considered negative. Plasma ADAMTS13 antigen (ADAMTS13:Ag) levels were determined by ELISA as described. 20 The reference range of the assay was 403 -907 ng/mL; the limit of quantification was 10 ng/mL. Levels of 100 -403 ng/mL were considered reduced; levels <100 ng/mL as severely reduced; values <10 ng/mL as undetectable.
Detection of free anti-ADAMTS13 antibodies by ELISA
Free antibodies were detected as described 25 with modifications (Supplementary Methods).
Detection of ADAMTS13-specific ICs
Microtiter plates were coated with a polyclonal rabbit anti-human ADAMTS13 antibody.After blocking the non-specific sites, diluted patient plasma samples and controls were added and incubated overnight at 4°C. The next day, the immunoglobulin fraction of the bound ICs was detected with horseradish peroxidase-conjugated class-specific secondary antibodies followed by detection with an appropriate chromogenic substrate. For details, see
Supplementary Methods and Supplementary Figure S1 .
An ELISA to detect total IgG-ICs was not established, however, the total amount of IgG-ICs was investigated in selected patients by co-immunoprecipitation as described 23 (Supplementary Methods).
Statistical calculations
Levels of free and complexed anti-ADAMTS13 antibodies were expressed as titers (Supplementary Methods).
Data are presented as the median with the range in brackets. Statistical significance of the differences between values for the acute phase and remission was assessed by MannWhitney rank sum test. The strength of the relation between different variables was analyzed using Spearman rank correlation. A P-value of <0.05 was considered significant. All statistical analyses were performed with SigmaPlot (Systat Software, San Jose, CA, USA). ADAMTS13-specific ICs were detected in 9/10 patients, mainly of subclass IgG4 (8/9 patients), with a median titer of 100 (50-200), however, IgG1-ICs and IgG2-ICs were also detected in a few patients (2/9 patients in both instances). There were no statistically significant differences in ADAMTS13 activity, ADAMTS13 functional inhibitor titers or free and complexed anti-ADAMTS13 antibody titers between rituximab-treated and non-treated patients in remission (not shown). From the patients treated with rituximab, only 1/10 (10%) patient relapsed, whereas 5/18 (28%) patients (median remission of 6 months; range 6 months -1.5 year) not treated with rituximab relapsed.
RESULTS
Detection
DISCUSSION
The pathogenesis of aTTP is characterized by severe ADAMTS13 deficiency due to anti-ADAMTS13 autoantibodies, inhibiting its activity or enhancing its clearance. 3;5;7;26 Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody ICs that might exert a potentially pathogenic role. In the present study, we determined the prevalence of free and complexed anti-ADAMTS13 antibodies in 78 aTTP patients.
ADAMTS13-specific ICs were detected in most patients during the acute event (97%; n=68) and in remission (93%; n=28), with IgG4-ICs as the predominant subclass.
ADAMTS13-specific ICs were detected with a newly developed ELISA-based assay and, as a complementary method, a co-IP assay. 23 In the ELISA, a polyclonal anti-ADAMTS13
antibody was used to capture ADAMTS13-specific ICs present in plasma; the composition of the immunoglobulin fraction of the ICs was revealed by antibodies directed against human The most relevant finding of our study was the detection of IgG-ICs in 93% of patients in remission, independent of remission length. This strongly indicates that ADAMTS13-specific ICs circulates in aTTP patients during the entire course of the disease and many years after clinical remission. That ICs were detectable in remission despite normalization of other ADAMTS13-related parameters might be explained by a low-level steady-state production of autoantibodies that is triggered by follicular dendritic cells. These accessory immune cells are frequently found in autoimmune diseases to retain ICs on their surface for years thereby providing a constant antigen depot for memory B-cell stimulation. 27 Since only a limited number of patients (6/28; 21%) tested in remission relapsed, the clinical relevance of circulating ADAMTS13-specific ICs in remission remains to be established in prospective studies.
Free anti-ADAMTS13 IgGs were mainly of subclasses IgG1 and IgG4, in accordance with previous studies, 8;9 and no IgG subclass switch was observed between the acute phase and in remission. For most patients, the distribution of subclasses for free and complexed IgG anti-ADAMTS13 antibodies correlated, suggesting a similar avidity for ADAMTS13 among IgG subclasses. Interestingly though, ADAMTS13-specific ICs were predominantly of subclass IgG4 (92% of patients during the acute phase and also 92% in remission), whereas all other subclasses were detected at a substantially lower rate ( Figure 1 ).
IgG4 is usually the least effective IgG subclass in terms of final effector functions because of its inability to activate complement via the classical pathway and its low affinity to cellular Fcγ receptors (FcγR). 28 The extent to which IgG4 elicits effector functions depends on the immunoglobulin's environment. As a free monomer, IgG4 only interacts with high-affinity 35 The resulting longer plasma half-life of IgG4-ICs might contribute to their preferred detection in the TTP patients' samples.
Although the effector functions are limited, a pathogenic role has been described for IgG4 in certain autoimmune diseases, such as recruitment and activation of neutrophils, induction of leucocyte-dependent dermal-epidermal separation and leucocyte-dependent tissue damage.
At least in some cases, these effects appear to be independent of complement activation and FcγR binding [36] [37] [38] ; however, the role of IgG4 antibodies in the pathogenesis of aTTP needs further investigation.
Analysis of three patients during treatment and remission confirmed the presence of ADAMTS13-specific ICs throughout the observation period ( Figure 3 ). This is consistent with results for a previously described patient with refractory aTTP. 23 Furthermore, the inverse correlation between free and complexed anti-ADAMTS13 antibodies seen in this patient during treatment was also discernible for the three patients during the early acute event while on PEX. However, no clear such trend was found in remission. These findings may reflect the continuous variation in levels of ADAMTS13, auto-antibodies and ICs throughout PEX therapy which also determines the rate of IC formation and clearance. It appears that the free and complexed antibodies' course during treatment is complex and depends on treatment modalities as well as patients' individual response.
The current standard treatment for acute idiopathic TTP is PEX and immunosuppressive therapy with corticosteroids. Over the last years, rituximab, a humanized antibody that targets CD20 expressed on mature and memory B cells but not on plasma cells 39 , has successfully been administered as an adjuvant therapy for refractory and relapsing aTTP, and treated patients seem to benefit through long-lasting remission. [40] [41] [42] [43] In our study, we found that the 10 patients treated with rituximab during the acute event still had detectable free and/or complexed anti-ADAMTS13 antibodies in remission; in some of the long-term remission patients ADAMTS13-specific ICs were detectable even after years. Moreover, there was no significant difference in free and complexed anti-ADAMTS13 antibodies titers to patients not treated with rituximab.
In summary, we provide the first comprehensive study on the presence of ADAMTS13-specific ICs in a large cohort of aTTP patients. ADAMTS13-specific ICs persisted in a vast majority during remission, even with normal ADAMTS13:Ac and ADAMTS13:Ag levels.
Whether determination of circulating ADAMTS13-specific ICs in remission is of value in predicting potential relapse needs to be further investigated. Most ICs contained IgG4, a subclass with limited effector functions, likely only neutralizing ADAMTS13 activity; nonetheless, future work needs to address the role of ADAMTS13-bound IgG4 antibodies in the pathogenesis of aTTP. Renal involvement* in acute phase / n 17/58
Neurological involvement in acute phase / n 22/55 n, number of patients with available information *Renal involvement was considered when creatinine levels were >1.2 mg/dL ADAMTS13:Ac, severely reduced levels <0.10 U/mL (<10%); reduced levels between 0.10 -0.50 U/mL and normal levels >0.5 U/mL. ADAMTS13:Ag, severely reduced levels <100 ng/mL and reduced levels between 100 -403 ng/mL. A minus sign denotes not calculated. *Total number of plasma samples available for analysis = 60. 
In vitro generation of ADAMTS13-specific immune complexes
ADAMTS13-specific ICs were generated in vitro by spiking 0, 1, 2, 5, 10 or 20 µg/mL of rADAMTS13 into plasma samples containing free anti-ADAMTS13 antibodies and into NHP as control. Samples were incubated for 2 h at 37°C, aliquoted and frozen at -80°C until testing.
Development of ELISA-based assays to detect ADAMTS13-specific ICs
Comparative analyses of free and complexed anti-ADAMTS13 antibodies in plasma from a large cohort of patients required development of ELISA-based assays capable of detecting the immunoglobulin fraction of the ADAMTS13-specific ICs. To evaluate the specificity and sensitivity of these ELISAs, ICs were generated in vitro by spiking increasing concentrations of rADAMTS13 into plasma from two aTTP patients (containing either free IgG1 and IgG3 or IgG2 and IgG4 anti-ADAMTS13 antibodies) and into NHP as control. Supplemental Figure   1A shows that ADAMTS13-specific IgG (1-4) ICs indeed accumulated in a rADAMTS13
concentration-dependent manner until saturation; this increase was accompanied by a decrease in corresponding free antibodies. NHP showed no detectable increase in ADAMTS13-specific ICs (Supplementary Figure 1A) .
Similar results were obtained when analyzing these samples using a co-IP method. The band intensity of ADAMTS13 that had been precipitated with total IgG through Protein G increased with greater amounts of spiked rADAMTS13 (Supplemental Figure 1Bi) . The relative amounts of IgG-IC reached saturation for both patient samples, whereas spiking of rADAMTS13 into NHP did not yield discernible ADAMTS13-specific ICs (Supplementary Figure 1Bii) .
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